HEALTHSTAT NEWS
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
- Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
- STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
- New weight-loss drug Retatrutide showing stronger results than current options
- Experimental obesity drug outperforms traditional weight-loss treatments in early research